Printer Friendly

NEWLY FORMED GALAGEN INC. TO DEVELOP BIOPHARMACEUTICALS FROM MILK

 NEWLY FORMED GALAGEN INC. TO DEVELOP BIOPHARMACEUTICALS FROM MILK


Products to Prevent Secondary Infections in Immunocompromised Patients
 ST. PAUL, Minn., Aug. 10 /PRNewswire/ -- GalaGen Inc., a newly formed biotechnology company, named its management team and announced it has secured its first infusion of private outside funding.
 GalaGen's primary technology focuses on separating antibody proteins from dairy milk for use in passive immunotherapy. Passive immunity in its purest form is a mother providing antibody proteins to her infant through breast feeding, which protects the infant from disease. Products developed by GalaGen initially will target infections of the gastrointestinal tract. People who would benefit from GalaGen's milk- derived products are ulcer patients and patients with immune deficiencies. GalaGen has several therapeutic products in various stages of development, including two in Phase II clinical trials. Long- term, GalaGen also expects to develop nutritional and pharmaceutical products based on high-value proteins separated from the milk of transgenic animals.
 GalaGen currently is funded through a recent $6.1 million private placement. The company intends to seek additional funding through the private or public markets, as well as through corporate alliances.
 John R. Sheppard, Ph.D., is GalaGen's chairman and chief executive officer. He was previously vice president, corporate finance for Vector Securities International, Inc., Deerfield, Ill., and held the same position at Kidder Peabody & Co. in New York City. Prior to that, Sheppard was professor of genetics and cell biology at the University of Minnesota.
 Blair P. Mowery, GalaGen's president and chief operating officer, was a co-founder of PROCOR Technologies, GalaGen's predecessor company and a wholly-owned subsidiary of agricultural cooperative Land O'Lakes. He served as president and general manager of PROCOR since its inception in 1987.
 Leonard P. Ruiz, Jr., Ph.D., the company's senior vice president and chief scientific officer, also was a co-founder of PROCOR. He served as that company's vice president of research and development and was director of the same function for Land O'Lakes since 1987.
 Michael E. Cady is GalaGen's vice president of operations. He was a co-founder of PROCOR and its director of operations since its founding.
 GalaGen Inc., based in the Twin-Cities suburb of Arden Hills, Minn., was formed in May 1992 through the spin-off and renaming of PROCOR Technologies, which had been a subsidiary of Land O'Lakes. PROCOR developed and delivered several commercially successful products for the animal health market. Land O'Lakes has retained rights to these animal products and also holds a minority interest in GalaGen. GalaGen's current offices are at 4001 Lexington Ave. N., Arden Hills, Minn., 55126.
 -0- 8/10/92
 /CONTACT: John Swenson of Swenson Falker Eilertsen Inc., 612-371-0000, for GalaGen Inc./ CO: GalaGen ST: Minnesota IN: SU: PDT


MA -- MN019 -- 8724 08/10/92 17:57 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 10, 1992
Words:455
Previous Article:KNAPE & VOGT MFG. FOURTH-QUARTER NET RISES 38 PERCENT ON 6-PERCENT SALES INCREASE
Next Article:FIRST U.S. DECISION ON STEEL SHOWS NEED FOR ACCORD, SAYS CANDIAN FLAT-ROLLED STEEL PRODUCERS
Topics:


Related Articles
WALLIN TO JOIN GALAGEN BOARD
GALAGEN INC. NAMES DR. ROBERT A. HOERR PRESIDENT AND COO
GALAGEN'S SPORIDIN-G QUALIFIES FOR ORPHAN DRUG DESIGNATION
NEW CARDIOVASCULAR COMPANY LAUNCHED BY CAMBRIDGE, MA. TECHNOLOGY DEVELOPMENT FIRM
GALAGEN INC. FILES REGISTRATION STATEMENT FOR INITIAL PUBLIC OFFERING
GALAGEN ANNOUNCES 2,000,000 SHARE OFFERING AT $10.00 PER SHARE
GALAGEN ANNOUNCES 2,000,000 SHARE OFFERING AT $10.00 PER SHARE
GalaGen Inc. Announces Third Quarter Results
CytoMed Appoints Grace Yeh, Ph.D. As Chief Scientific Officer.
Genzyme Transgenics and ImmunoGen Collaborate on huN901 Production.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters